Literature DB >> 3334723

Class III gene rearrangements in Thai/Chinese supratypes containing null or defective C4 alleles.

P H Kay1, E Martin, R L Dawkins, P Charoenwong.   

Abstract

Class III gene rearrangements have been examined in Thai/Chinese individuals with supratypes bearing defective or null C4 alleles. Genomic DNA from C4 null supratypes was probed with an almost full-length 21-OH probe following digestion with Taq I and Kpn I. The HLA-B17 C4A3 BQ0 BfS DR3 Thai/Chinese supratypes (which may be associated with insulin-dependent diabetes mellitus in Orientals) lacks a 3.2 kb Taq I and a 3.9 kb Kpn I fragment hybridizing with the 21-OH probe. Similar gene rearrangements are found in Caucasoid diabetogenic supratypes HLA-B18 C4A3 BQ0 BfF1 DR3 and HLA-B8 C4AQ0 B1 BfS DR3. Interethnic comparisons suggest that class II and class III interactions may be important in disease susceptibility. By contrast, neither of two Thai/Chinese supratypes with C4AQ0 appear to have major class III gene rearrangements; disease association studies will determine the significance of C4 deficiency per se. As in Caucasoids, the electrophoretically fast C4 allele, C4A6, in Orientals has been shown to correlate with a 12 kb Bgl II fragment hybridizing with a C4 probe. It is likely that the HLA-B17 C4A6 B1 BfS DR7 supratype marks a highly conserved MHC chromosomal segment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3334723     DOI: 10.1007/bf00404443

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  16 in total

1.  HLA-DRw3 in juvenile onset diabetes mellitus in Chinese.

Authors:  H Maeda; F Takeuchi; T Juji; Y Akanuma; M Kasuga; Y S Lee; K Kosaka; S H Tsai
Journal:  Tissue Antigens       Date:  1980-02

2.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

3.  Bf in early-onset insulin-dependent diabetes.

Authors:  J Bertrams; P Sodemann; D Grüneklee; F A Gries
Journal:  Lancet       Date:  1979-12-08       Impact factor: 79.321

Review 4.  Molecular genetics of the fourth component of human complement and steroid 21-hydroxylase.

Authors:  M C Carroll; K T Belt; A Palsdottir; Y Yu
Journal:  Immunol Rev       Date:  1985-10       Impact factor: 12.988

5.  Rearrangement of 21-hydroxylase genes in disease-associated MHC supratypes.

Authors:  M J Garlepp; A N Wilton; R L Dawkins; P C White
Journal:  Immunogenetics       Date:  1986       Impact factor: 2.846

6.  The coexistence of IgA deficiency and 21-hydroxylase deficiency marked by specific MHC supratypes.

Authors:  T J Cobain; M S Stuckey; J McCluskey; A N Wilton; A Gedeon; M J Garlepp; F T Christiansen; R L Dawkins
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

7.  Correlation between a DNA restriction fragment length polymorphism and C4A6 protein.

Authors:  A Palsdottir; S J Cross; J H Edwards; M C Carroll
Journal:  Nature       Date:  1983 Dec 8-14       Impact factor: 49.962

8.  Disease associations with complotypes, supratypes and haplotypes.

Authors:  R L Dawkins; F T Christiansen; P H Kay; M Garlepp; J McCluskey; P N Hollingsworth; P J Zilko
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

9.  Different HLA antigen associations for the functionally active and inactive products of the complement C4F1 allele.

Authors:  G J O'Neill; P Miniter; M S Pollack; B Dupont
Journal:  Hum Immunol       Date:  1980-07       Impact factor: 2.850

10.  Susceptibility to IDDM is marked by MHC supratypes rather than individual alleles.

Authors:  H Kelly; V J McCann; P H Kay; R L Dawkins
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

View more
  1 in total

1.  Extensive deletions and insertions in different MHC supratypes detected by pusled field gel electrophoresis.

Authors:  K Tokunaga; G Saueracker; P H Kay; F T Christiansen; R Anand; R L Dawkins
Journal:  J Exp Med       Date:  1988-09-01       Impact factor: 14.307

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.